Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

LNP1265

Gene therapy (Lentiviral vector) · Gene replacement: Factor IX (F9)

Phase 1/2 Most advanced trial
1 Registered trials

What is LNP1265?

LNP1265 is a lentiviral gene therapy for hemophilia B that delivers the Factor IX gene to restore clotting factor production.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy (Lentiviral vector)
Targets
Factor IX (F9)
Mechanism
Gene replacement: Factor IX (F9)
Therapy area
Hematology
In trials of
NTLA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06379789 Phase 1/2 Hemophilia B Recruiting NTLA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hemophilia B

Other drugs acting on F9

REGV131 Phase 1/2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.